How much did ChemoCentryx achieve in EBIT for the current year?
In the current year, ChemoCentryx has achieved an EBIT of 144.57 M USD.
ChemoCentryx EBIT 2024
ChemoCentryx EBIT
144.57 M USD
Ticker
CCXI
ISIN
US16383L1061
WKN
A0NBM2
In 2024, ChemoCentryx's EBIT was 144.57 M USD, a -1,062.23% increase from the -15.02 M USD EBIT recorded in the previous year.
The ChemoCentryx EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2026e | 885.83 |
| 2025e | 354.33 |
| 2024e | 144.57 |
| 2023e | -15.02 |
| 2022e | -122.73 |
| 2021 | -129.92 |
| 2020 | -55.18 |
| 2019 | -58.3 |
| 2018 | -40.27 |
| 2017 | 16.49 |
| 2016 | -40.72 |
| 2015 | -47.69 |
| 2014 | -47.4 |
| 2013 | -39.12 |
| 2012 | -39.63 |
| 2011 | -4.3 |
| 2010 | -5.96 |
| 2009 | 15.7 |
| 2008 | -20.13 |
| 2007 | -19.14 |
| 2006 | -19.14 |
ChemoCentryx Revenue, EBIT, Net Income US16383L1061 · A0NBM2
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ChemoCentryx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ChemoCentryx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ChemoCentryx’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ChemoCentryx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ChemoCentryx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ChemoCentryx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ChemoCentryx’s growth potential.
ChemoCentryx Revenue, Profit, and EBIT History
| Date | ChemoCentryx Revenue | ChemoCentryx EBIT | ChemoCentryx Net Income |
|---|---|---|---|
| 2026e | 1.3 B undefined | 885.83 M undefined | 666.74 M undefined |
| 2025e | 841.57 M undefined | 354.33 M undefined | 266.7 M undefined |
| 2024e | 412.67 M undefined | 144.57 M undefined | 108.81 M undefined |
| 2023e | 224.88 M undefined | -15.02 M undefined | -16.13 M undefined |
| 2022e | 73.85 M undefined | -122.73 M undefined | -121.79 M undefined |
| 2021 | 32.22 M undefined | -129.92 M undefined | -131.76 M undefined |
| 2020 | 64.89 M undefined | -55.18 M undefined | -55.36 M undefined |
| 2019 | 36.13 M undefined | -58.3 M undefined | -55.49 M undefined |
| 2018 | 42.88 M undefined | -40.27 M undefined | -37.97 M undefined |
| 2017 | 82.5 M undefined | 16.49 M undefined | 17.86 M undefined |
| 2016 | 11.94 M undefined | -40.72 M undefined | -39.96 M undefined |
| 2015 | 0 undefined | -47.69 M undefined | -47.31 M undefined |
| 2014 | 0 undefined | -47.4 M undefined | -46.93 M undefined |
| 2013 | 6.06 M undefined | -39.12 M undefined | -38.67 M undefined |
| 2012 | 5.42 M undefined | -39.63 M undefined | -39.89 M undefined |
| 2011 | 31.67 M undefined | -4.3 M undefined | -4.62 M undefined |
| 2010 | 34.86 M undefined | -5.96 M undefined | -3.1 M undefined |
| 2009 | 49.74 M undefined | 15.7 M undefined | 15.62 M undefined |
| 2008 | 24.09 M undefined | -20.13 M undefined | -18.47 M undefined |
| 2007 | 20.74 M undefined | -19.14 M undefined | -15.69 M undefined |
| 2006 | 8.11 M undefined | -19.14 M undefined | -17.34 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 8.11 M USD | -19.14 M USD | -17.34 M USD |
| 2007 | 20.74 M USD | -19.14 M USD | -15.69 M USD |
| 2008 | 24.09 M USD | -20.13 M USD | -18.47 M USD |
| 2009 | 49.74 M USD | 15.7 M USD | 15.62 M USD |
| 2010 | 34.86 M USD | -5.96 M USD | -3.1 M USD |
| 2011 | 31.67 M USD | -4.3 M USD | -4.62 M USD |
| 2012 | 5.42 M USD | -39.63 M USD | -39.89 M USD |
| 2013 | 6.06 M USD | -39.12 M USD | -38.67 M USD |
| 2014 | 0 USD | -47.4 M USD | -46.93 M USD |
| 2015 | 0 USD | -47.69 M USD | -47.31 M USD |
| 2016 | 11.94 M USD | -40.72 M USD | -39.96 M USD |
| 2017 | 82.5 M USD | 16.49 M USD | 17.86 M USD |
| 2018 | 42.88 M USD | -40.27 M USD | -37.97 M USD |
| 2019 | 36.13 M USD | -58.3 M USD | -55.49 M USD |
| 2020 | 64.89 M USD | -55.18 M USD | -55.36 M USD |
| 2021 | 32.22 M USD | -129.92 M USD | -131.76 M USD |
| 2022e | 73.85 M USD | -122.73 M USD | -121.79 M USD |
| 2023e | 224.88 M USD | -15.02 M USD | -16.13 M USD |
| 2024e | 412.67 M USD | 144.57 M USD | 108.81 M USD |
| 2025e | 841.57 M USD | 354.33 M USD | 266.7 M USD |
| 2026e | 1.3 B USD | 885.83 M USD | 666.74 M USD |
ChemoCentryx stock margins US16383L1061 · A0NBM2
The ChemoCentryx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ChemoCentryx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ChemoCentryx.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ChemoCentryx's sales revenue. A higher gross margin percentage indicates that the ChemoCentryx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ChemoCentryx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ChemoCentryx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ChemoCentryx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ChemoCentryx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ChemoCentryx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ChemoCentryx Margin History
| ChemoCentryx Gross margin | ChemoCentryx Profit margin | ChemoCentryx EBIT margin | ChemoCentryx Profit margin |
|---|---|---|---|
| 2026e | 99.06 % | 68.35 % | 51.45 % |
| 2025e | 99.06 % | 42.1 % | 31.69 % |
| 2024e | 99.06 % | 35.03 % | 26.37 % |
| 2023e | 99.06 % | -6.68 % | -7.17 % |
| 2022e | 99.06 % | -166.21 % | -164.93 % |
| 2021 | 99.06 % | -403.17 % | -408.87 % |
| 2020 | 99.06 % | -85.04 % | -85.31 % |
| 2019 | 99.06 % | -161.36 % | -153.58 % |
| 2018 | 99.06 % | -93.91 % | -88.55 % |
| 2017 | 99.06 % | 19.99 % | 21.65 % |
| 2016 | 99.06 % | -341.04 % | -334.67 % |
| 2015 | 99.06 % | 0 % | 0 % |
| 2014 | 99.06 % | 0 % | 0 % |
| 2013 | 99.06 % | -645.54 % | -638.12 % |
| 2012 | 99.06 % | -731.18 % | -735.98 % |
| 2011 | 99.06 % | -13.58 % | -14.59 % |
| 2010 | 99.06 % | -17.1 % | -8.89 % |
| 2009 | 99.06 % | 31.56 % | 31.4 % |
| 2008 | 99.06 % | -83.56 % | -76.67 % |
| 2007 | 99.06 % | -92.29 % | -75.65 % |
| 2006 | 99.06 % | -236 % | -213.81 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 99.06 % | -236 % | -213.81 % |
| 2007 | 99.06 % | -92.29 % | -75.65 % |
| 2008 | 99.06 % | -83.56 % | -76.67 % |
| 2009 | 99.06 % | 31.56 % | 31.4 % |
| 2010 | 99.06 % | -17.1 % | -8.89 % |
| 2011 | 99.06 % | -13.58 % | -14.59 % |
| 2012 | 99.06 % | -731.18 % | -735.98 % |
| 2013 | 99.06 % | -645.54 % | -638.12 % |
| 2014 | 99.06 % | 0 % | 0 % |
| 2015 | 99.06 % | 0 % | 0 % |
| 2016 | 99.06 % | -341.04 % | -334.67 % |
| 2017 | 99.06 % | 19.99 % | 21.65 % |
| 2018 | 99.06 % | -93.91 % | -88.55 % |
| 2019 | 99.06 % | -161.36 % | -153.58 % |
| 2020 | 99.06 % | -85.04 % | -85.31 % |
| 2021 | 99.06 % | -403.17 % | -408.87 % |
| 2022e | 99.06 % | -166.21 % | -164.93 % |
| 2023e | 99.06 % | -6.68 % | -7.17 % |
| 2024e | 99.06 % | 35.03 % | 26.37 % |
| 2025e | 99.06 % | 42.1 % | 31.69 % |
| 2026e | 99.06 % | 68.35 % | 51.45 % |
ChemoCentryx Aktienanalyse
What does ChemoCentryx do?
ChemoCentryx Inc. was founded in 1997 and is based in Mountain View, California. The company specializes in the development of medications for rare autoimmune diseases, cancer, and inflammation. Since its founding, ChemoCentryx Inc. has developed a variety of drug candidates, some of which are in clinical phases or as finished products. The business model of ChemoCentryx Inc. is based on the discovery and development of medications targeting chemokines and chemokine receptors. This technology allows for the regulation and control of inflammatory processes. The company also utilizes its proprietary Janus kinase inhibitors (JAK inhibitors) for the treatment of inflammatory diseases. ChemoCentryx Inc. has several business areas. The primary area is the research and development of medications that can be used as candidates against inflammatory, cancer, autoimmune, and fibrosis diseases. The second significant area is collaboration with international partners in the research and development of these medications. The company has also developed specialized tools and technologies to optimize its drug development processes. These techniques include high-throughput screening and X-ray crystallography technologies, as well as biomarker-based diagnostics. One important product of ChemoCentryx Inc. is Avacopan, an oral medication used in the treatment of ANCA-associated vasculitic diseases such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is a selective antagonist of the C5a receptor, which plays a central role in the inflammatory response. Clinical studies on the efficacy and safety of Avacopan have yielded promising results, and the medication has received Breakthrough Therapy Designation status from the US FDA. Additionally, ChemoCentryx Inc. has successfully identified candidates for the treatment of atopic dermatitis, lupus nephritis, and Crohn's disease. These products are still in the clinical development phase and have great potential to significantly improve the lives of patients suffering from these conditions. Overall, ChemoCentryx Inc. has made significant progress in the discovery and development of drugs that can combat inflammation and other chronic diseases. The company is well-positioned to expand its pipeline and bring additional breakthrough products to market that will play a crucial role in treating diseases that have been difficult to treat in the past. ChemoCentryx ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing ChemoCentryx's EBIT
ChemoCentryx's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of ChemoCentryx's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
ChemoCentryx's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in ChemoCentryx’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about ChemoCentryx Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company ChemoCentryx.
How has the EBIT of ChemoCentryx developed in recent years?
The EBIT of ChemoCentryx has increased by -1,062.233% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company ChemoCentryx?
The EBIT of ChemoCentryx is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does ChemoCentryx pay?
Over the past 12 months, ChemoCentryx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ChemoCentryx is expected to pay a dividend of 0 USD.
What is the dividend yield of ChemoCentryx?
The current dividend yield of ChemoCentryx is .
When does ChemoCentryx pay dividends?
ChemoCentryx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ChemoCentryx?
ChemoCentryx paid dividends every year for the past 0 years.
What is the dividend of ChemoCentryx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ChemoCentryx located?
ChemoCentryx is assigned to the 'Health' sector.
Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ChemoCentryx from 6/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/13/2024.
When did ChemoCentryx pay the last dividend?
The last dividend was paid out on 6/13/2024.
What was the dividend of ChemoCentryx in the year 2023?
In the year 2023, ChemoCentryx distributed 0 USD as dividends.
In which currency does ChemoCentryx pay out the dividend?
The dividends of ChemoCentryx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The ChemoCentryx stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von ChemoCentryx
Our stock analysis for ChemoCentryx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemoCentryx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- ChemoCentryx Revenue
- ChemoCentryx Net Income
- ChemoCentryx P/E
- ChemoCentryx P/S
- ChemoCentryx EBIT
- ChemoCentryx Dividend
- ChemoCentryx Stocks
- ChemoCentryx Market capitalization
- ChemoCentryx Debt
- ChemoCentryx Liabilities
- ChemoCentryx Equity
- ChemoCentryx AAQS
- ChemoCentryx Employees
- ChemoCentryx ROE
- ChemoCentryx ROA
- ChemoCentryx ROCE
